BioCentury Inc.

.@IAmBiotech CEO Crowley says Biosecure isn't coming back, MFN isn't going away, and there's a once-in-a-generation chance to modernize @US_FDA

The future of drug development is unfolding—are you ready to discover it? ?? Save your spot today! ?? #DrugDevelopment #DrugDevelopmentDisco #BiotechInnovation #PharmaFuture #BioCentury #SaveYourSpot

Managing @Novartis’ pipeline in an era of fast innovation. How CEO Vas Narasimhan views precision medicine, rising challenges in radioligand therapy, and the CAR T immune reset opportunity: in conversation with BioCentury's @FishburnSimone $NVS

Brett Zbar, Managing Director and Global Head of Life Sciences at General Atlantic, has joined the panel of our upcoming #CapitalMarketsPreview webinar. Join us to discuss the key drivers that dealmakers are watching that could help biotechs rise above the noise. ??? Register for the complimentary webinar on March 25: https://lnkd.in/gx5HZGSA

Dr Zahid Moneer, PhD MPhil MBA (Cantab), Senior Managing Director of Investment Banking at BNP Paribas, says biotech enthusiasm has surged since #JPM2025. ?? Moneer sees capital raises, from seed rounds to major series A, B, and C rounds, boosting the sector alongside increased M&A activity. He also discusses private equity’s rising role in biopharma, highlighting Bain Capital’s landmark buyout of Mitsubishi Tanabe. ?? Watch the full interview with BioCentury Inc.'s Executive Editor Jeff Cranmer on YouTube or listen on your favorite podcast platform:?https://lnkd.in/ghmvqCHD Access all of BioCentury's streaming commentary on industry trends and interviews with KOLs. Tune in to the #BioCenturyThisWeek and the #BioCenturyShow podcasts:?https://lnkd.in/gEWXhWMn

#Obesity hottest target #amylin gets its biggest deal yet as $ROG licenses co-dev/commercial rights to $ZEAL Ph II amylin agonist #petrelintide for $1.65B up front and up to $5.3B total; Roche's ambition in obesity and manufacturing capabilities gave it a leg up in what was a very competitive bidding war for #amylin therapy $NVO $LLY $AZN $GUBRA

?? Be the first to find the next scientific breakthroughs from academia, meeting global innovators at the?2nd BioCentury Grand Rounds - U.S.?in Chicago, June 4 - 6, 2025 — right after ASCO! Connect with emerging academic entrepreneurs as we showcase groundbreaking research, clinical insights and transformative technologies with significant commercial potential. ?? Investors: Register by April 11 to save with our special rate for VCs. Email "Investor" to [email protected] to receive the code. ?? Advanced rates end March 28: https://lnkd.in/g-Xb97sN Learn more about #BioCenturyGrandRounds - U.S.: https://lnkd.in/gQrYavRM #VCs #biopharma #translationalscience #drugdevelopment Join the LinkedIn event: https://lnkd.in/gPnFSjds

Distilling the Future: Innovation Hunting for the Next Chapter of Drug Development ?? The future of drug development is unfolding—are you ready to discover it? Join us next week, Thu, Mar 20, 2025, and learn how expert curation is uncovering hidden biomedical innovations, unlocking breakthrough targets and technologies from around the world. This is your chance to stay ahead of the curve and gain insights that could shape the next chapter of drug development. ? Save your spot today! ?? #DrugDevelopment #DrugDevelopmentDisco #BiotechInnovation #PharmaFuture #BioCentury #SaveYourSpot

More than 30 companies are testing autoimmune CAR Ts in the clinic. Are there enough patients and trial sites for all of them?